Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biostage, Inc. stock logo
BSTG
Biostage
$4.45
$4.45
$4.45
$4.45
$61.78M-1.021,847 shsN/A
Electromed, Inc. stock logo
ELMD
Electromed
$20.13
+0.5%
$21.03
$13.74
$35.56
$169.40M0.4180,302 shs31,444 shs
Nevro Corp. stock logo
NVRO
Nevro
$5.85
+0.1%
$5.85
$3.17
$10.37
$224.32M0.81802,711 shs753,602 shs
Nyxoah SA stock logo
NYXH
Nyxoah
$7.93
-0.6%
$7.32
$5.55
$11.87
$270.10M1.6275,583 shs17,146 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biostage, Inc. stock logo
BSTG
Biostage
0.00%0.00%0.00%0.00%0.00%
Electromed, Inc. stock logo
ELMD
Electromed
-0.50%-8.17%-4.44%-14.92%+34.91%
Nevro Corp. stock logo
NVRO
Nevro
0.00%0.00%0.00%0.00%-30.16%
Nyxoah SA stock logo
NYXH
Nyxoah
+1.53%+5.70%+4.04%+27.88%-5.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/AN/AN/AN/AN/A
Electromed, Inc. stock logo
ELMD
Electromed
1.5061 of 5 stars
2.05.00.00.00.61.70.6
Nevro Corp. stock logo
NVRO
Nevro
0.1777 of 5 stars
1.00.00.00.00.01.70.6
Nyxoah SA stock logo
NYXH
Nyxoah
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biostage, Inc. stock logo
BSTG
Biostage
0.00
N/AN/AN/A
Electromed, Inc. stock logo
ELMD
Electromed
4.00
Strong Buy$38.0088.77% Upside
Nevro Corp. stock logo
NVRO
Nevro
1.92
Reduce$5.36-8.29% Downside
Nyxoah SA stock logo
NYXH
Nyxoah
3.00
Buy$14.5082.85% Upside

Current Analyst Ratings Breakdown

Latest BSTG, NVRO, NYXH, and ELMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Electromed, Inc. stock logo
ELMD
Electromed
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/21/2025
Nyxoah SA stock logo
NYXH
Nyxoah
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/A($0.26) per shareN/A
Electromed, Inc. stock logo
ELMD
Electromed
$61.44M2.75$0.49 per share41.36$5.10 per share3.95
Nevro Corp. stock logo
NVRO
Nevro
$408.52M0.55N/AN/A$8.10 per share0.72
Nyxoah SA stock logo
NYXH
Nyxoah
$4.89M55.23N/AN/A$3.60 per share2.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biostage, Inc. stock logo
BSTG
Biostage
-$6.07M-$0.58N/AN/AN/AN/A-174.43%N/A
Electromed, Inc. stock logo
ELMD
Electromed
$5.15M$0.7926.93N/A11.34%15.71%13.37%N/A
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)
Nyxoah SA stock logo
NYXH
Nyxoah
-$64.10M-$2.13N/AN/AN/A-1,571.39%-63.37%-46.67%8/5/2025 (Estimated)

Latest BSTG, NVRO, NYXH, and ELMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Nyxoah SA stock logo
NYXH
Nyxoah
-$0.60N/AN/AN/A$1.33 millionN/A
5/14/2025Q1 2025
Nyxoah SA stock logo
NYXH
Nyxoah
-$0.49-$0.63-$0.14-$0.63$1.64 million$1.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/AN/A
Electromed, Inc. stock logo
ELMD
Electromed
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A
Nyxoah SA stock logo
NYXH
Nyxoah
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biostage, Inc. stock logo
BSTG
Biostage
N/A
2.73
2.73
Electromed, Inc. stock logo
ELMD
Electromed
N/A
5.10
4.74
Nevro Corp. stock logo
NVRO
Nevro
0.67
5.02
3.76
Nyxoah SA stock logo
NYXH
Nyxoah
0.22
3.59
3.35

Institutional Ownership

CompanyInstitutional Ownership
Biostage, Inc. stock logo
BSTG
Biostage
N/A
Electromed, Inc. stock logo
ELMD
Electromed
40.82%
Nevro Corp. stock logo
NVRO
Nevro
95.52%
Nyxoah SA stock logo
NYXH
Nyxoah
N/A

Insider Ownership

CompanyInsider Ownership
Biostage, Inc. stock logo
BSTG
Biostage
15.30%
Electromed, Inc. stock logo
ELMD
Electromed
14.00%
Nevro Corp. stock logo
NVRO
Nevro
3.20%
Nyxoah SA stock logo
NYXH
Nyxoah
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Biostage, Inc. stock logo
BSTG
Biostage
713.88 million11.76 millionNot Optionable
Electromed, Inc. stock logo
ELMD
Electromed
1608.39 million7.36 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,09038.37 million36.27 millionOptionable
Nyxoah SA stock logo
NYXH
Nyxoah
11034.06 millionN/ANot Optionable

Recent News About These Companies

Brokers Set Expectations for Nyxoah FY2026 Earnings
Nyxoah SA (NYXH) Q1 2025 Earnings Call Transcript
Publication relating to transparency notifications

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biostage stock logo

Biostage OTCMKTS:BSTG

$4.45 0.00 (0.00%)
As of 07/24/2023

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.

Electromed stock logo

Electromed NYSE:ELMD

$20.13 +0.11 (+0.55%)
As of 11:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Nevro stock logo

Nevro NYSE:NVRO

$5.85 +0.01 (+0.10%)
Closing price 04/2/2025
Extended Trading
$5.85 0.00 (0.00%)
As of 04/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Nyxoah stock logo

Nyxoah NASDAQ:NYXH

$7.93 -0.05 (-0.63%)
As of 11:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.